ABBV - AbbVie Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
2024-06-12 19:12:07 ET
AbbVie, Inc. (ABBV)
Goldman Sachs 45th Annual Global Healthcare Conference
June 12, 2024 10:00 AM ET
Company Participants
Robert Michael - President & COO
Jeffrey Stewart - EVP & Chief Commercial Officer
Roopal Thakkar - SVP & Chief Medical Officer, Global Therapeutics
Scott Reents - EVP & CFO
Conference Call Participants
Chris Shibutani - Goldman Sachs
Presentation
Chris Shibutani
Welcome everybody. Glad that you can join us. My name is Chris Shibutani, member at the Goldman Sachs Healthcare Research team. We are thrilled to have such a great representation from AbbVie across the C-suite, including our incoming CEO, Chief Operating Officer currently and President, Rob Michael, who we spoke last year.
Robert Michael
Yes.
Chris Shibutani
We should -- everybody should listen very carefully to what you say, because you mean what you say. So we'll look forward to this conversation as well. Scott Reents, Chief Financial Officer; sorry, Jeff Stewart. We do have Scott, who is present here. Is he in the ecosystem? He is kind of hiding. So we'll see how much he can escape. And then Roopal Thakkar from the Research Organization. So thank you very much for joining us.
Robert Michael
Thanks for having us, Chris.
Question-and-Answer Session
Q - Chris Shibutani
We always manage to find or maybe it's always the case for AbbVie that there are some sentinel junctures. It's hard to keep you guys out of the spotlight, but we're post 2023, such a momentous year. You guys navigated extremely well through that, as we get through 2024, and with the announcement of your ascendancy. Talk to us about how you're feeling about where the company is at? Just big picture and then we'll dive deeper.
Robert Michael
Yeah. Look, I'm very -- thanks for having us, Chris. I'm very pleased with the performance of the business. When you think about the ex-Humira platform, it makes up more than 80% of our revenue now. It's growing in the mid-teens. It's allowed us to return to revenue growth just one year after the U.S. Humira LOE, which no one in our industry has ever experienced. It also positions us very well for return of robust growth next year. And we would define that as being above industry average. Industry average is low-single digits....
AbbVie, Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)